Skip Navigation


Carcinogenesis Advance Access originally published online on January 16, 2004
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
25/6/967    most recent
bgh082v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (19)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Young, M. V.
Right arrow Articles by Chen, T. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Young, M. V.
Right arrow Articles by Chen, T. C.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Carcinogenesis, Vol. 25, No. 6, 967-971, June 2004
Carcinogenesis vol.25 no.6 © Oxford University Press 2004; all rights reserved.


ARTICLE

The prostate 25-hydroxyvitamin D-1{alpha}-hydroxylase is not influenced by parathyroid hormone and calcium: implications for prostate cancer chemoprevention by vitamin D

Michael V. Young1, Gary G. Schwartz2, Lilin Wang1, Daniel P. Jamieson1, Lyman W. Whitlatch, John N. Flanagan1, Bal L. Lokeshwar3, Michael F. Holick1 and Tai C. Chen1,4

1 Section of Endocrinology, Diabetes and Nutrition, Boston University School of Medicine, Boston, MA 02118, USA, 2 Department of Cancer Biology, Comprehensive Cancer Center of Wake Forest University, Winston-Salem, NC 27157, USA and 3 Department of Urology, University of Miami School of Medicine, Miami, FL 33101, USA

4 To whom correspondence should be addressed at Room M-1022, Boston University Medical Center, 715 Albany Street, Boston, MA 02118, USA Email: taichen{at}bu.edu

The hormonal form of vitamin D, 1{alpha},25-dihydroxyvitamin D [1{alpha},25(OH)2D] promotes the differentiation and inhibits the proliferation, invasiveness and metastasis of prostate cells. However, 1{alpha},25(OH)2D is not suitable as a chemopreventive agent because its administration can cause hypercalcemia. Serum levels of 1{alpha},25(OH)2D are tightly regulated by the renal enzyme, 25-hydroxyvitamin D-1{alpha}-hydroxylase (1{alpha}-OHase), which synthesizes 1{alpha},25(OH)2D from the prohormone, 25-hydroxyvitamin D [25(OH)D]. Normal prostate epithelial cells in primary culture, as well as several prostate cancer cell lines, also express 1{alpha}-OHase and synthesize the hormone intracellularly. We now investigated the regulation of the prostate 1{alpha}-OHase by the three most important regulators of the renal 1{alpha}-OHase: calcium, 1{alpha},25(OH)2D and parathyroid hormone (PTH). The 1{alpha}-OHase activity in the primary cultures of prostate epithelial cells was inhibited by 1{alpha},25(OH)2D3 at 10 and 100 nM, whereas PTH at 10 and 100 nM had no significant effect. Calcium at 1.2 and 2.4 mM had no significant effect on the enzyme activity in the PZ-HPV-7 cell line, a prostate epithelial cell line derived from normal prostate tissue. Conversely, 1.2 or 2.4 mM calcium markedly inhibited 1{alpha}-OHase activity in a human kidney cell line used as a positive control. Furthermore, PTH at 100 nM and calcium at 1.2 and 2.4 mM had no effect on the 1{alpha}-OHase gene promoter activity in prostate cells, whereas the promoter activity was inhibited 48 ± 5% by 100 nM 1{alpha},25(OH)2D3. Our findings suggest that, unlike the renal enzyme, the prostate 1{alpha}-OHase appears to be largely unregulated by serum levels of PTH and calcium. These findings support the hypothesis that vitamin D or 25(OH)D may be useful as chemopreventive agents for prostate cancer because their administration should cause an increased synthesis of 1{alpha},25(OH)2D within prostate cells.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Anticancer ResHome page
R. VIETH
How to Optimize Vitamin D Supplementation to Prevent Cancer, Based on Cellular Adaptation and Hydroxylase Enzymology
Anticancer Res, September 1, 2009; 29(9): 3675 - 3684.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Clin. Nutr.Home page
C. M Weaver
Should dairy be recommended as part of a healthy vegetarian diet? Point
Am. J. Clinical Nutrition, May 1, 2009; 89(5): 1634S - 1637S.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
S. Hansdottir, M. M. Monick, S. L. Hinde, N. Lovan, D. C. Look, and G. W. Hunninghake
Respiratory Epithelial Cells Convert Inactive Vitamin D to Its Active Form: Potential Effects on Host Defense
J. Immunol., November 15, 2008; 181(10): 7090 - 7099.
[Abstract] [Full Text] [PDF]


Home page
J. Nutr.Home page
J. C. Fleet, C. Gliniak, Z. Zhang, Y. Xue, K. B. Smith, R. McCreedy, and S. A. Adedokun
Serum Metabolite Profiles and Target Tissue Gene Expression Define the Effect of Cholecalciferol Intake on Calcium Metabolism in Rats and Mice
J. Nutr., June 1, 2008; 138(6): 1114 - 1120.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
N. Urushino, S. Nakabayashi, M. A. Arai, A. Kittaka, T. C. Chen, K. Yamamoto, K. Hayashi, S. Kato, M. Ohta, M. Kamakura, et al.
Kinetic Studies of 25-Hydroxy-19-nor-vitamin D3 and 1{alpha},25-Dihydroxy-19-nor-vitamin D3 Hydroxylation by CYP27B1 and CYP24A1
Drug Metab. Dispos., September 1, 2007; 35(9): 1482 - 1488.
[Abstract] [Full Text] [PDF]


Home page
Integr Cancer TherHome page
M. F. McCarty and K. I. Block
Toward a Core Nutraceutical Program for Cancer Management
Integr Cancer Ther, June 1, 2006; 5(2): 150 - 171.
[Abstract] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
D. Teegarden, P. Legowski, C. W. Gunther, G. P. McCabe, M. Peacock, and R. M. Lyle
Dietary Calcium Intake Protects Women Consuming Oral Contraceptives from Spine and Hip Bone Loss
J. Clin. Endocrinol. Metab., September 1, 2005; 90(9): 5127 - 5133.
[Abstract] [Full Text] [PDF]


Home page
Integr Cancer TherHome page
M. F. McCarty
Targeting Multiple Signaling Pathways as a Strategy for Managing Prostate Cancer: Multifocal Signal Modulation Therapy
Integr Cancer Ther, December 1, 2004; 3(4): 349 - 380.
[Abstract] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.